SBIR/STTR Research Award

Integrated System for Rapid Production of Activated Sugars and Glycosylated Molecules

Award identifier a1f07accff274479b09f2d54a557be4fcd6a4b597780947863ae6aea72642bd0Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$147,325

Program and phase

SBIR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ZUCHEM INC.
Proposal award date
2018-08-01
Contract end date
2019-04-30
UEI
LHZKXV13TLJ7
Solicitation number
PA16-302
Topic code
300

Research abstract

Glycan modifications of natural products are increasingly important in the discovery of new pharmaceuticalsWhile glycodiversity gives rise to important therapeutic properties of bioactive moleculesexploring glycodiversity has challengesIsolating glycosylated compounds from nature is often difficult due to low concentrations and the presence of multiple related molecules with similar structures and propertiesChemical synthesis is challenging task and may only produce small milligram amountsThe enzymatic synthesis of glycans has many potential advantages for producing both natural and novel compounds is significantly limited by the availability of the activated NDP sugar substrates required by glycosyltransferases involved in the glycosylation reactionsAt zuChem we have engineered proprietary enzymes involved in activated sugar synthesis including sugar kinases and nucleotidyltransferase with broadened substrate specificities producing a wide range of sugarphosphates and activated sugarsThe enzymes are stable and carry out reactions quickly and at high titerDespite thishoweverchallenges remain with their use on a rapid and broad scaleThe enzymes exhibit product and substrate inhibition and run under different physiological reaction conditionsThis prevents a simple one pot method for activated sugars to be developedintermediates need complex purification before use in the next reaction stepAs a resultthroughput and the ability to produce larger volumes of activated sugars is limitedFinallythe cost of nucleotides remains expensive for large scale production of compoundsHerewe propose to develop an integrated system for simple production of a large library of natural and novel activated NDP sugarsThe system will contain enzymes engineered to eliminate substrate product inhibition and work under similar physiological conditionsThey will be utilized in a one pot or immobilized setup with a nucleotide recycling systemStarting from the proprietary enzymes we have developed we will use a powerful screen we have designed to rapidly identify mutants with improved enzyme propertiesIn Phase I we will demonstrate the feasibility of developing the systemWe will show that a polyphosphate kinase can be engineered to tolerate higher levels of the ADP co productand a nucleotidyltransferase can be engineered with decreased sensitivity to nucleotidesIn Phase II we will further improve the enzymesoptimize mutation combinations and optimize the cofactor recycling systemWe will also develop one pot and or enzyme immobilization methods to create an integrated system for the rapid production of activated sugarsThe system will be able to produce not only activated sugarsbut custom glycosylated products when fed only sugarcatalytic amounts of nucleotide triphosphatesNTPpolyphosphateand the customer s desired glycosyltransferase and substrateAt preparative and industrial scales the system will be adapted for the production of important oligosaccharidesIn Phase III we will commercialize the system by selling or licensing it for use to researchersand selling custom activated sugarsoligosaccharides and other glycosylated compounds Project Narrative We will develop a novel integrated system for the enzymatic synthesis of activated sugars with in situ nucleotide regenerationThis technology will simplify production of a large library of both natural and rare activated sugars nucleotidesmake them more readily available at research scale for glycodiversity experiments and at large scale for production of glycosylated small moleculesproteinsand oligosaccharidesThe proposed research has the potential to open up several multi billion dollar markets in anti infective and anticancer therapeutics

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

16 SBIR/STTR records share this UEI (2005–2018). Reported award amounts total $6,534,146. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, National Science Foundation, Department of Energy

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.